Analysts Set Actinium Pharmaceuticals, Inc. (NYSE:ATNM) PT at $11.43

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among […]

Leave a Reply

Your email address will not be published.

Previous post Analysts Set Altair Engineering Inc. (NASDAQ:ALTR) Target Price at $90.67
Next post Analysts Set Independence Realty Trust, Inc. (NYSE:IRT) Price Target at $18.17